Posted January 30, 2007
RESEARCH TRIANGLE PARK, N.C. – CeNeRx BioPharma has received Food and Drug Administration approval to launch testing of its lead drug candidate on humans.
The drug, Tyrima, is targeted as a treatment for depression and anxiety. Tyrima is one of several candidates being developed by CeNeRx, which has already raised $25 million in venture capital. Among its investors is Pappas Ventures, which is based in RTP.
CeNeRx recently met with the FDA to discuss its new drug application.
Tyrima is based on reversible inhibitors of monoamine oxidase A, or RIMA. RIMA based antidepressants are already sold in Europe. RIMA drugs elevate levels of three neurotransmitters that affect mood and anxiety rather than other antidepressants that focus on one neurotransmitter.
"Initiation of human trials for Tyrima is an important milestone for CeNeRx, marking our transition to a clinical stage company," said Barry Brand, chief executive officer of CeNeRx, in a statement.
If the drug is approved it would be the first RIMA antidepressant available in the U.S. CeNeRx owns worldwide rights to Tyrima.
In the U.S. alone, nearly 15 million adults deal with what the National Institute of Mental Health calls “major depressive disorders.”Copyright 2010 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
CeNeRx Prepares To Launch First Clinical Trial for Lead Drug
Post a comment
Print this storyE-mail story
Share
The drug, Tyrima, is targeted as a treatment for depression and anxiety. Tyrima is one of several candidates being developed by CeNeRx, which has already raised $25 million in venture capital. Among its investors is Pappas Ventures, which is based in RTP.
CeNeRx recently met with the FDA to discuss its new drug application.
Tyrima is based on reversible inhibitors of monoamine oxidase A, or RIMA. RIMA based antidepressants are already sold in Europe. RIMA drugs elevate levels of three neurotransmitters that affect mood and anxiety rather than other antidepressants that focus on one neurotransmitter.
"Initiation of human trials for Tyrima is an important milestone for CeNeRx, marking our transition to a clinical stage company," said Barry Brand, chief executive officer of CeNeRx, in a statement.
If the drug is approved it would be the first RIMA antidepressant available in the U.S. CeNeRx owns worldwide rights to Tyrima.
In the U.S. alone, nearly 15 million adults deal with what the National Institute of Mental Health calls “major depressive disorders.”Copyright 2010 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Featured
Hot Off The Wire
- Hot Off the Wire – AT&T CEO’s pay soars to $20.2M; Analyst downgrades Yahoo; Motorola adds Bing to smartphones
- Hot Off the Wire – Net naming agency reconsiders ‘xxx’ domain; Huge botnet taken down; Google to digitize historic books in Rome, Florence
- Hot Off the Wire – MySpace plans makeover after exec shakeup; Early PC designer wins Turning technology award; Cisco competitor share’s jump
Venture & Innovation
- CED picks nine more companies to present at venture conference
- Venture Briefs – A top VC uses blog to generate wider dealfow; CA pays $350M for cloud computing firm; Battery closes on $750M fund
- Venture briefs – 10th birthday for ‘dot-com bubble’ peak; ‘Startup Bus’ teams entrepreneurs for ideas; Carried interest debate is back; Weebly adds theme site creation tool
E-mail Preferences
